The early predication of Alzheimer's disease based on intelligent radiomics technology
YAO Xufeng1, YUAN Zengbei1,2, BU Xixi1,2
1. College of Medical Imaging, Shanghai University of Medicine and Health Sciences, Shanghai 201318, China;
2. School of Medical Instrument and Food Engineering, University of Shanghai for Science and Technology, Shanghai 200093, China
Abstract：The Alzheimer's disease (AD) is usually insidious in its onset and there are no drugs or methods to effectively control and treat the disease. Early prediction and intervention during the stage of the mild cognitive impairment (MCI) can effectively delay the course of the disease. The review contains two aspects. One is the early clinical diagnosis of the AD based on the brain imaging radiomics features, another is the AD early prediction based on the artificial intelligence (AI) of the imaging radiomics. We propose that in the framework of the deep learning, the imaging and the genomics are combined to construct a deep learning model with a high classification and prediction performance, to provide support for early screening and intervention of the AD.
姚旭峰, 袁增贝, 卜溪溪. 基于智能影像基因组学技术的阿尔茨海默病预测进展[J]. 科技导报, 2021, 39(20): 101-109.
YAO Xufeng, YUAN Zengbei, BU Xixi. The early predication of Alzheimer's disease based on intelligent radiomics technology. Science & Technology Review, 2021, 39(20): 101-109.
[1] Lim B, Prassas I, Diamandis E P. Alzheimer disease pathogenesis:The role of autoimmunity[J]. The Journal of Applied Laboratory Medicine, 2021, 6(3):756-764.
[2] Patterson C. World Alzheimer report 2018. The state of the art of dementia research:New frontiers, 2018[J]. Alzheimer's Disease International, 2018, 9(1):29-35.
[3] Xu J F, Wang J, Anders W, et al. The economic burden of dementia in China, 1990-2030:Implications for health policy[J]. Bulletin of the World Health Organization, 2017, 95(1):18-26.
[4] Fu J, Bao F Q, Gu M, et al. Design, synthesis and evaluation of quinolinone derivatives containing dithiocarbamate moiety as multifunctional AChE inhibitors for the treatment of Alzheimer's disease[J]. Journal of enzyme inhibition and medicinal chemistry, 2020, 35(1):118-128
[5] Alzheimer's Association. 2018 Alzheimer's disease facts and figures[J]. Alzheimer's & Dementia, 2018, 14(3):367-429.
[6] Albert M, Zhu Y, Moghekar A, et al. Predicting progression from normal cognition to mild cognitive impairment for individuals at 5 years[J]. Brain, 2018, 141(3):877-887.
[7] Bachurin S O, Gavrilova S I, Samsonova A, et al. Mild cognitive impairment due to Alzheimer disease:Contemporary approaches to diagnostics and pharmacological intervention[J]. Pharmacological Research, 2017:S1043661817309374.
[8] Frederiksen K S, Gjerum L, Waldemar G, et al. Effects of physical exercise on Alzheimer's disease biomarkers:A systematic review of intervention studies[J]. Journal of Alzheimer's Disease, 2018, 61(1):359-372.
[9] Bachurin S O, Gavrilova S I, Samsonova A, et al. Mild cognitive impairment due to Alzheimer disease:Contemporary approaches to diagnostics and pharmacological intervention[J]. Pharmacological Research, 2018, 129(3):216-226.
[10] Nagaratnam N, Nagaratnam K, Cheuk G. Mild cognitive impairment (MCI)[M]. Berlin:Springer International Publishing, 2017.
[11] Eratne D, Loi S M, Farrand S, et al. Alzheimer's disease paper clinical update on epidemiology, pathophysiology and diagnosis[J]. Australasian Psychiatry, 2018:103985621876230.
[12] Chételat G. Multimodal neuroimaging in Alzheimer's disease:Early diagnosis, physiopathological mechanisms, and impact of lifestyle[J]. Journal of Alzheimer's Disease, 2018, 64(Suppl 1):1-13.
[13] Santos P, Leide C, Ozela P F, et al. Alzheimer's disease:A review from the pathophysiology to diagnosis, new perspectives for pharmacological treatment[J]. Current medicinal chemistry, 2018, 25(26):3141-3159.
[14] Cox S R, Bastin M E, Ritchie S J, et al. Brain cortical characteristics of lifetime cognitive aging[J]. Brain Structure and Function, 2018, 223(1):509-518.
[15] Cotier F A, Zhang R, Lee T M C. A longitudinal study of the effect of short-term meditation training on functional network organization of the aging brain[J]. Scientific Reports, 2017, 7(598):1-11.
[16] Beason-Held L L, Hohman T J, Venkatraman V, et al. Brain network changes and memory decline in aging[J]. Brain Imaging & Behavior, 2017, 11(3):1-15.
[17] Yao X H, Shan C, Yan J W, et al. Regional imaging genetic enrichment analysis[J]. Bioinformatics, 2020, 36(8):2554-2560.
[18] Bajaj S, Alkozei A, Dailey N S, et al. Brain aging:Uncovering cortical characteristics of healthy aging in young adults[J]. Frontiers in Aging Neuroscience, 2017, 9:412.
[19] Gomar J J, Ragland J D, Uluğ A M, et al. Differential medial temporal lobe morphometric predictors of itemand relational-encoded memories in healthy individuals and in individuals with mild cognitive impairment and Alzheimer's disease[J]. Alzheimers & Dementia Translational Research & Clinical Interventions, 2017, 3(2):238-246.
[20] Lee S H, Bachman A H, Yu D, et al. Predicting progression from mild cognitive impairment to Alzheimer's disease using longitudinal callosal atrophy[J]. Alzheimers & Dementia, 2016, 2:68-74.
[21] Dicks E, Tijms B M, Ten Kate M, et al. Gray matter network measures are associated with cognitive decline in mild cognitive impairment[J]. Neurobiology of Aging, 2018, 61(1):198-206.
[22] Henf J, Grothe M J, Brueggen K, et al. Mean diffusivity in cortical gray matter in Alzheimer's disease:The importance of partial volume correction[J]. Neuroimage Clinical, 2018, 17(17):579-586.
[23] Reas E T, Hagler Jr D J, White N S, et al. Microstructural brain changes track cognitive decline in mild cognitive impairment[J]. NeuroImage:Clinical, 2018, 20(9):883-891.
[24] Farrar D C, Mian A Z, Budson A E, et al. Retained executive abilities in mild cognitive impairment are associated with increased white matter network connectivity[J]. European Radiology, 2018, 28(1):340-347.
[25] Daianu M, Jahanshad N, Nir T M, et al. Rich club analysis in the Alzheimer's disease connectome reveals a relatively undisturbed structural core network[J]. Human Brain Mapping, 2015, 36(8):3087-3103.
[26] Fischer F U, Wolf D, Scheurich A, et al. Altered wholebrain white matter networks in preclinical Alzheimer's disease[J]. NeuroImage:Clinical, 2015, 8(6):660-666.
[27] Cantero J L, Atienza M, Sanchez-Juan P, et al. Cerebral changes and disrupted gray matter cortical networks in asymptomatic older Adults at risk for Alzheimer's disease[J]. Neurobiology of Aging, 2018, 64(4):58-67.
[28] Klaassens B L, van G J M A, Jeroen V D G, et al. Diminished posterior precuneus connectivity with the default mode network differentiates normal aging from Alzheimer's disease[J]. Frontiers in Aging Neuroscience, 2017, 9:97.
[29] Martínez G, Vernooij R W, Fuentes P P, et al. 18F PET with florbetapir for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI)[J]. Cochrane Database Systematic Reviews, 2017, 11(2):CD012883.
[30] Nakamura A, Kaneko N, Villemagne V L, et al. High performance plasma amyloid-β biomarkers for Alzheimer's disease[J]. Nature, 2018, 554(7691):249.
[31] Olsson B, Lautner R, Andreasson U, et al. CSF and blood biomarkers for the diagnosis of Alzheimer's disease:A systematic review and meta-analysis[J]. Lancet Neurology, 2016, 15(7):673-684.
[32] Niculescu A, Le N H, Roseberry K, et al. O45. Blood biomarkers for possible early detection of risk for Alzheimer disease (AD)[J]. Biological Psychiatry, 2019, 85(10):S124.
[33] Zhang J, Shi S L. A literature review of AD7c-ntp as a biomarker for Alzheimer's disease[J]. Annals of Indian Academy of Neurology, 2013, 16(3):307.
[34] Hellwig K, Kvartsberg H, Portelius E, et al. Neurogranin and YKL-40:Independent markers of synaptic degeneration and neuroinflammation in Alzheimer's disease[J]. Alzheimers Research & Therapy, 2015, 7(1):1-8.
[35] Kumar S, Reddy P H. Are circulating microRNAs peripheral biomarkers for Alzheimer's disease?[J]. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease, 2016:S0925443916301429.
[36] Franke B, Stein J L, Ripke S, et al. Genetic influences on schizophrenia and subcortical brain volumes:Largescale proof of concept[J]. Nature Neuroscience, 2016, 19(3):420-431.
[37] Hao X K, Yao X H, Risacher S, et al. Identifying candidate genetic associations with MRI-derived AD-related ROI via tree-guided sparse learning[J]. IEEE/ACM Transactions on Computational Biology & Bioinformatics, 2018, 99:1-4.
[38] Cacciaglia R, Molinuevo J L, Falcón C, et al. Effects of APOE-ε4 allele load on brain morphology in a cohort of middle-aged healthy individuals with enriched genetic risk for Alzheimer's disease[J]. Alzheimers & Dementia, 2018, 14(7):902-912.
[39] Tangaro S, Fanizzi A, Amoroso N, et al. A fuzzy-based system reveals Alzheimer's disease onset in subjects with mild cognitive impairment[J]. Physica Medica, 2017, 38(5):36-44.
[40] Pagani M, Nobili F, Morbelli S, et al. Early identification of MCI converting to AD:A FDG PET study[J]. European Journal of Nuclear Medicine & Molecular Imaging, 2017, 44(12):2042-2052.
[41] Çevik A, Weber G W, Eyüboğlu B M, et al. VoxelMARS:A method for early detection of Alzheimer's disease by classification of structural brain MRI[J]. Annals of Operations Research, 2017, 258(1):31-57.
[42] Moradi E, Pepe A, Gaser C, et al. Machine learning framework for early MRI-based Alzheimer's conversion prediction in MCI subjects[J]. Neuroimage, 2015, 104(1):398-412.
[43] Liu X N, Chen K W, Wu T, et al. Use of multimodality imaging and artificial intelligence for diagnosis and prognosis of early stages of Alzheimer's disease[J]. Translational Research, 2018, 194(4):56-67.
[44] Basaia S, Agosta F, Wagner L, et al. Automatic classification of patients with Alzheimer's disease (AD) and mild cognitive impairment (MCI) who will convert to AD using deep neural networks[J]. Neurology, 2018, 90(Suppl 15):179.
[45] Lu D, Popuri K, Ding G W, et al. Multi-scale deep neural networks based analysis of FDG-PET images for the early diagnosis of Alzheimer's disease[J]. Medical Image Analysis, 2018:S1361841518300276.
[46] Shi J, Zhen X, Li Y, et al. Multimodal neuroimaging feature learning with multimodal stacked deep polynomial networks for diagnosis of alzheimer's disease[J]. IEEE Journal Biomedical and Health Informatics, 2018, 22(1):173-183.
[47] Raju M, Gopi V P, Anitha V S, et al. Multi-class diagnosis of Alzheimer's disease using cascaded three dimensional-convolutional neural network[J]. Physical and Engineering Sciences in Medicine, 2020, 43(4):1219-1228.
[48] Khvostikov A, Aderghal K, Benois-Pineau J, et al. 3D CNN-based classification using sMRI and MD-DTI images for Alzheimer disease studies[J]. arXiv, 2018:1801.05968.
[49] Lim B, van der Schaar M. Forecasting disease trajectories in Alzheimer's disease using deep learning[J]. arXiv, 2018:1807.03159.
[50] Ning K D, Chen B, Sun F Z, et al. Classifying Alzheimer's disease with brain imaging and genetic data using a neural network framework[J]. Neurobiology of Aging, 2018, 68:151-158.
[51] Lu D, Popuri K, Ding W, et al. Multimodal and multiscale deep neural networks for the early diagnosis of Alzheimer's Disease using structural MR and FDG-PET images[J]. Scientific Reports, 2018, 8(1):5697.
[52] Zhang Y P, Wang S H, Xia K J, et al. Alzheimer's disease multiclass diagnosis via multimodal neuroimaging embedding feature selection and fusion[J]. Information Fusion, 2021, 66:170-183.
[53] Zhou T, Thung K H, Zhu X, et al. Effective feature learning and fusion of multimodality data using stagewise deep neural network for dementia diagnosis[J]. Human Brain Mapping, 2019, 40(3):1001-1016.
[54] Spasov S, Passamonti L, Duggento A, et al. A parameterefficient deep learning approach to predict conversion from mild cognitive impairment to Alzheimer's disease[J]. NeuroImage, 2019, 189(4):276-287.
[55] Khagi B, Kwon G R, Lama R. Comparative analysis of Alzheimer's disease classification by CDR level using CNN, feature selection, and machine-learning techniques[J]. International Journal of Imaging Systems and Technology, 2019, 29(3):297-310.
[56] Razavi F, Tarokh M J, Alborzi M. An intelligent Alzheimer's disease diagnosis method using unsupervised feature learning[J]. Journal of Big Data, 2019, 6(1):1-16.
[57] Shen T, Jiang J, Lu J, et al. Predicting Alzheimer disease from mild cognitive impairment with a deep belief network based on 18F-FDG-PET Images[J]. Molecular imaging, 2019, 18(1):1536012119877285.
[58] Usman S M, Khalid S, Aslam M H. Epileptic seizures prediction using deep learning techniques[J]. IEEE Access, 2020, 8:39998-40007.
[59] Suk H I, Lee S W, Shen D G, et al. Hierarchical feature representation and multimodal fusion with deep learning for AD/MCI diagnosis[J]. NeuroImage, 2014, 101(1):569-582.
[60] Suk H I, Lee S W, Shen D G. Latent feature representation with stacked auto-encoder for AD/MCI diagnosis[J]. Brain Structure and Function, 2015, 220(2):841-859.
[61] Suk H l, Shen D G. Deep learning-based feature representation for AD/MCI classification[J]. Medical Image Computing and Computer-assisted Intervention:MICCAI International Conference on Medical Image Computing and Computer-Assisted Intervention, 2013, 16(Pt 2):583-590.
[62] Liu S, Liu S, Cai W, et al. Multi-modal neuroimaging feature learning for multi-class diagnosis of Alzheimer's disease[J]. IEEE Transactions on Biomedical Engineering, 2015, 62(4):1132-1140.
[63] Goceri E, Goceri N. Deep learning in medical image analysis:Recent advances and future trends[J]. IEEE Access, 2017:305-311
[64] Battineni G, Chintalapudi N, Amenta F, et al. Acomprehensive machine-learning model applied to magnetic resonance imaging (MRI) to predict Alzheimer's disease (AD) in older subjects[J]. Journal of Clinical Medicine, 2020, 9(7):2146.
2021, Vol. 39 
